



01-14-05

1631
Jew

Express Mail No.: EV 533 736 026 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Baxter et al. Confirmation No.: 7561
Serial No.: 09/281,717 Art Unit: 1631
Filed: March 30, 1999 Examiner: Moran, M.
For: METHODS AND COMPOUNDS FOR Attorney Docket No.: 61040-0008-US
MODULATING NUCLEAR RECEPTOR
COACTIVATOR BINDING

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

1. Enclosures accompanying this Information Disclosure Statement are:
 - 1a. A list of all patents, publications, applications, or other information submitted for consideration by the office.
 - 1b. A legible copy of:
 - Each U.S. patent application publication and U.S. and foreign patent;
 - Each publication or that portion which caused it to be listed on the PTO-1449;
 - For each cited pending U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion;
 - all other information or portion which caused it to be listed on the PTO-1449.
 - 1c. An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report.
 - 1d. Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications.

2. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
- Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - Before the mailing of the first Office action on the merits;
 - Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.
- (Check either Item 3a or 3b)*
- 3a. The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
 enclosed
 to be charged to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310 (order no.).
- (Item 3b to be checked if any reference known for more than 3 months)*
4. This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.
- (Check either Item 4a or 4b)*
- 4a. The Certification Statement in Item 5 below is applicable.
- 4.b The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:
 enclosed
 to be charged to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310 (order no.).
5. Certification Statement (applicable if Item 3a or Item 4a is checked)
- (Check either Item 5a, 5b or 5c)*
- 5a. In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- 5b. Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6. Copies of each cited U.S. patent and each U.S. patent application publication are not enclosed pursuant to the USPTO OG Notice dated 05 August 2003 waiving the requirement under 37 C.F.R. 1.98(a)(2)(i) for U.S. patent applications filed after June 30, 2003.
7. This application is a continuation application under 37 C.F.R. §1.53(b) or (d).

(Check appropriate Items 7a, 7b and/or 7c)

- 7a. A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 7b. Copies of publications listed on Form PTO-1449 from prior application Serial No. _____, filed on _____, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 7c. Copies of the publications listed on Form PTO-1449 were not previously cited in prior application Serial No. _____, filed on _____, and are provided herewith.
8. This is a Supplemental Information Disclosure Statement. (Check Item 8a)
- 8a. This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on _____. A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on _____.
9. In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:

(Check Item 9a, 9b, or 9c)

- 9a. satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 9b. set forth in the application.
- 9c. enclosed as an attachment hereto.

10. The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310 (order no. 61040-0008-US).
11. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).

Respectfully submitted,

Date: January 12, 2005

R. G. A. Bone

Richard G.A. Bone
Limited Recognition Under 37 C.F.R. §11.9(b)
(Copy of Certificate Attached hereto)

for Thomas D. Kohler, Reg. No. 32,797
MORGAN, LEWIS & BOCKIUS LLP
2 Palo Alto Square
3000 El Camino Real, Suite 700
Palo Alto, CA 94306
(650) 843-4000